Midas will assist ABP in the introduction, marketing and promotion of the Accu-Break Technologies to potential collaboration partners. Additionally, Midas may assist ABP in the preparation of regulatory information and in communications with health authorities and European opinion leaders to promote the licensing of the Accu-Break Technologies.
Allan Kaplan, ABP’s CEO, said: “This agreement with Midas will help broaden the opportunities available to ABP to license the patented and patent pending Accu-Break Technologies worldwide.”